Empagliflozin Attenuates Ferroptosis in Acute Myocardial Infarction via the AMPK/NRF2/SLC7A11 Signaling Pathway
International Heart Journal · 31.07.2026 · 67 (4) · 381-395
DOI: 10.1536/ihj.25-386 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Heart Journal, erschienen am 31.07.2026. Verfasst von Xiangrui Tang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, 3201 Hospital of Xi'an Jiaotong University Health Science Center. Hauptthemen laut MEDLINE: Ferroptosis, NF-E2-Related Factor 2, Myocardial Infarction, AMP-Activated Protein Kinases. Die Arbeit nennt 49 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, 3201 Hospital of Xi'an Jiaotong University Health Science Center.
- Catheter Room, The Affiliated Hospital of Yan'an University.
- Department of Pharmacy, Baoji Central Hospital.
Zitieren
APA
Tang, X., Zhao, X., & Liu, C. (2026). Empagliflozin Attenuates Ferroptosis in Acute Myocardial Infarction via the AMPK/NRF2/SLC7A11 Signaling Pathway. International Heart Journal, 67(4), 381-395. https://doi.org/10.1536/ihj.25-386
Vancouver
Tang X, Zhao X, Liu C. Empagliflozin Attenuates Ferroptosis in Acute Myocardial Infarction via the AMPK/NRF2/SLC7A11 Signaling Pathway. International Heart Journal. 2026;67(4):381-395. doi:10.1536/ihj.25-386
BibTeX
@article{Tang2026,
author = {Tang, Xiangrui and Zhao, Xiaoxia and Liu, Chunjun},
title = {Empagliflozin Attenuates Ferroptosis in Acute Myocardial Infarction via the AMPK/NRF2/SLC7A11 Signaling Pathway},
journal = {International Heart Journal},
year = {2026},
volume = {67},
number = {4},
pages = {381--395},
doi = {10.1536/ihj.25-386}
}
EUVIMED